PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v6i3.4019ArticleClinical Value of Peripheral Blood Circulating Tumor Cells and Cell-Free DNA Combined Detection in Triple-Negative Breast Cancerhttps://artdesignp.com/journal/PAR/6/3/10.26689/par.v6i3.4019SunJirui,MaShuangqui,ChenHong,GengHuijuan,ZhangJinku2022632022-05-30Objective: To determine the clinical value of combined detection of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) in peripheral blood of patients with triple-negative breast cancer. Method: 41 patients with breast cancer admitted to the First Central Hospital of Baoding from January 2020 to December 2021 were selected and recruited into the experimental group, 42 patients with benign breast cancer admitted during the same period were recruited into the conditional control group, and 41 healthy patients admitted during the same period were recruited into the blank control group. The positive rate of peripheral blood CTCs, the level of cfDNA, and the diagnostic efficacy of peripheral blood CTCs, cfDNA alone and the combination thereof for breast cancer were analyzed. Result: The positive rates of peripheral blood CTCs in the experimental group, the conditional control group, and the blank control group were 43.90%, 11.90%, and 9.74%, respectively, and there was significant difference among the groups. The levels of cfDNA in peripheral blood of the experimental group, the conditional control group, and the blank control group were 0.26 ± 0.08 bp, 0.17 ± 0.03 bp, and 0.15 ± 0.04 bp, respectively, which were statistically significant. The detection levels of 100 bp hTERT/ng·ml-1 and 241 bp hTERT/ng·ml-1 in the experimental group were significantly higher than those in the conditional control group and the blank control group. The accuracy of peripheral blood CTCs detection in the three groups was 66.21%, the accuracy of cfDA241 bp / 100 bp hTERT detection was 80.41%, and the accuracy of combined detection of peripheral blood CTCs and cfDNA was 94.03%. Conclusion: The clinical application of peripheral blood CTCs combined with cfDNA level detection can increase detection accuracy, provide data support for clinicians, and improve the clinical diagnostic effect of triple-negative breast cancer.

Yu X, Li T, Cong Z, et al., 2022, Combined Detection of hMAM, SBEM and ceacam19mrna in Peripheral Blood of Patients with Breast Cancer and its Clinical Significance. Journal of Jilin University (Medical Edition), 48(01): 195-202.

Li M, Yang Z, Gao W, et al., 2021, HIF-2 in Peripheral Blood ? Expression Level and Clinical Significance of Th17/Treg Cells in Patients with Breast Cancer. Journal of Tropical Medicine, 21(12): 1542-1567.

Zhang J, Zhang Y, Dong X, 2021, Progress of Long-Chain Noncoding RNA in Peripheral Blood in the Diagnosis of Breast Cancer.Chinese Journal of Hygienic Inspection, 31(24): 3068-3073.

Wan R, Zhu C, Deng Y, et al., 2021, Interleukin-1?, Interleukin-6 and ? Expression and Significance of 2-Microglobulin in Peripheral Blood of Patients with Breast Cancer. Chinese Modern Doctor, 59(34): 128-131.

Jin X, Gu D, Zhang Y, et al., 2021, Changes of TM, TF and CGRP Levels in Peripheral Blood of Chemotherapy-Related Bloodstream infection in breast cancer [j/ol] Chinese Journal of nosocomial Infection, 2021(23): 3576-3580.

Wang S, Zou M, Ou J, et al., 2021, Lrg1 and TNF-? Changes and Clinical Significance of Expression Level in Peripheral Blood of Patients with Breast Cancer. Systems Medicine, 6(22): 1-4.

Zhou X, Lei S, Li L, et al., 2021, Correlation Between Methylation Level of EMR3 Gene in Peripheral Blood and Breast Cancer in Chinese Women. Journal of Southern Medical University, 41(10): 1456-1463.

Wang C, Qi J, He T, et al., 2021, The Value of Peripheral Blood SEPTIN9 Gene Methylation in the Diagnosis of Breast Cancer and the Evaluation of Chemotherapy Efficacy. Chinese Journal of Health Medicine, 23(03): 228-230.

Wang J, Lv X, Wu Z, et al., 2021, Study on the Relationship Between Circulating Tumor Cells and Clinicopathological Features of Breast Cancer. Chinese Journal of Oncology Surgery, 13(03): 242-245.

Dang S, Xu M, Hu Ji, et al., 2021, Influence of Peripheral Blood Inflammation Index Level on Prognosis of HER-2 Positive Breast Cancer Patients. Medical Theory and Practice, 34(11): 1810-1813, 1825.

Yuan K, Song Q, Lv S, et al., 2021, Research Progress of Peripheral Blood PD-1/PD-L1 in Breast Cancer. Electronic Journal of Tumor Metabolism and Nutrition, 8(03): 326-331.

Zhu C, 2021, Peripheral Blood TNF-? Study on the Correlation Between Routine Blood Indexes and Pathological Characteristics of Breast Cancer Patients, Nanchang University.

Chen G, 2021, Research Progress in the Application of Circulating Tumor DNA Detection in the Treatment of Advanced Breast Cancer, Shantou University.

Zhang Z, 2021, The Value of Serum CEA, CA19-9 and Peripheral Blood T Cell Subsets in Evaluating the Effect of Breast Cancer Surgery. Medical Theory and Practice, 34(07): 1091-1093.

Yan J, Zhou G, 2021, Expression of Autophagy Related Genes in Peripheral Blood Monocytes of Breast Cancer and its Relationship with Tumor Recurrence. Journal of Clinical Surgery, 29(03): 258-260.

Fan X, Fu J, Liu J, 2021, Detection of Circulating Tumor Cells and Circulating Free DNA in Peripheral Blood in Patients with Breast Cancer. Journal of Diagnostic Pathology, 28(01): 47-50, 54.

He Z, 2020, Establishment of DNA Methylation Detection Method and its Application in Serum Samples of Breast Cancer, Hunan University of Technology.

Zhang X, Jia C, Chen H, et al., 2019, Clinical Value of Combined Detection of Tumor Cells and Free DNA in Peripheral Blood Circulation in Auxiliary Diagnosis of Breast Cancer. Chinese Journal of Laboratory Medicine, 2019(08): 642-668.

Zhong M, 2019, Detection of Methylation of HIC-1 and Slit2 in Plasma Free DNA and its Significance in the Diagnosis of Breast Cancer, Shanghai Jiaotong University.

Gu L, Li M, Fan L, et al., 2019, Advances in the Application of Circulating Tumor DNA Detection in Breast Cancer. Chinese Journal of Practical Surgery, 39(02): 185-188.